RAPT - CIK 0001673772
RAPT Therapeutics, Inc. (RAPT) reported net income of -$129.87M for fiscal year 2024, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2024 | -$129.87M | -11.2% |
| FY 2023 | -$116.80M | -39.3% |
| FY 2022 | -$83.84M | -21.1% |
| FY 2021 | -$69.20M | -30.8% |
| FY 2020 | -$52.89M | -23.0% |
| FY 2019 | -$43.00M | -19.0% |
| FY 2018 | -$36.15M | - |
RAPT Therapeutics, Inc. (RAPT) reported net income of -$129.87M for fiscal year 2024, as filed in its audited annual report with the SEC.
Between fiscal 2018 and fiscal 2024, RAPT Therapeutics, Inc.'s net income declined from -$36.15M to -$129.87M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.